AstraZeneca.

Title character count (max 180, including spaces): 172 Word count (max 4500): 4255 Figs/Tables: 4 References (max 30

This study confirms that adjuvant imatinib has an overt impact on RFS. No significant difference in IFFS was observed, although in the high-risk subgroup there was a trend in favor of the adjuvant arm. IFFS was conceived as a potential end point in the adjuvant setting because it is sensitive to secondary resistance, which is the main adverse prognostic factor in patients with advanced GIST.